CurifyLabs Raises $14M for 3D-Printed Personalized Medicine
▼ Summary
– CurifyLabs, a Finnish startup, raised $14 million to expand its automated 3D-printing system for personalized medicines into U.S. pharmacies, where it already operates in 21 states.
– The company’s technology automates compounding—the manual process of creating custom drug doses for children, elderly patients, and those with rare conditions—using software and pharmaceutical-grade 3D printers.
– Its PharmaPrinter Aurum is ISO 13485 certified, complies with FDA rules for non-sterile compounding, and prints doses up to nine times faster than hand compounding.
– The Series A round was co-led by Sandwater and HealthCap, with participation from Finland’s Tesi and Lifeline Ventures, with funds allocated to U.S. expansion, supply chain, and R&D.
– Founded in 2021 by Charlotta Topelius and Niklas Sandler, CurifyLabs aims to bring personalized medicine to market through automated, on-site dose printing, building on a €6.7 million round from the previous year.
A Finnish startup is betting that the future of medicine will be printed, not poured, and it has secured $14 million to bring that vision to American pharmacies. The company, CurifyLabs, announced the close of a $14 million (€12 million) Series A funding round. Based in Helsinki, the firm develops both the machinery and software that allow pharmacies to 3D-print personalized medications on-site. This fresh capital will fuel its expansion deeper into the United States, where its technology is already operational in pharmacies across 21 states.
Most medications are manufactured in fixed, standard doses. However, children, elderly patients, and individuals with rare conditions frequently require a dosage that falls between those standard options or a completely different delivery form. Pharmacists have traditionally created these custom formulations by hand, a process known as compounding that is both slow and susceptible to human error. CurifyLabs automates this entire workflow. Its integrated system combines proprietary software, pharmaceutical-grade ingredient bases, and a 3D printer to produce tailored doses, complete with built-in quality control checks.
The company’s latest device, the PharmaPrinter Aurum, can compound medications up to nine times faster than manual methods. The technology holds ISO 13485 certification and is engineered to comply with the U. S. Food and Drug Administration’s regulations for non-sterile compounding.
The funding round was co-led by Sandwater and HealthCap, with participation from Finland’s state-backed investor Tesi and existing backer Lifeline Ventures. Several U. S. customers and staff members also contributed. The proceeds are earmarked for American market expansion, supply chain development, customer support, and further research. “Their growth in the U. S. is further proof that Finnish health technology can compete and win on the world stage,” said Joni Karsikas of Tesi. This push reflects a broader Nordic ambition, as other deep-tech firms from the region, like Espoo’s IQM, also target the U. S. market.
Founded in 2021 by CEO Charlotta Topelius and pharmaceutical scientist Niklas Sandler, CurifyLabs built this round on top of a €6.7 million raise last year. While the sum is modest compared to the trillions of dollars in the global pharmaceutical market, automating the complex, messy edges of drug dispensing represents a tangible and growing business opportunity. Other players are pursuing similar shifts, from automated, pharmacist-free dispensaries to a surge in European drug-tech funding and large-scale public precision-medicine initiatives. The concept of personalized medicine has felt perpetually on the verge of arrival. CurifyLabs is wagering that, one printed dose at a time, it will finally get there.
(Source: The Next Web)
